Company (Symbol)#

Date Filed

DateComm.

Shares/ Units (M)

Price

Shares Out (M)@

Lead, OtherUnderwriters

Gross(US$M)

Post-OfferingMarketCap (M)%

Horizon Pharma Inc. (Northbrook, Ill.; HZNP)1

8/3/10

7/29/11

5.5S

$9

19.5

Stifel Nicolaus Weisel

Cowen & Co. (co-lead)

JMP Securities (co-lead)

$49.5

$175.5

Total: $49.5M

Number of IPOs in July: 1

Average value of JULY IPOs: $49.5M

Number of IPOs in 20 1 1: 10

Total raised in IPOs in 20 1 1: $516.84M

Average value of IPOs in 20 1 1: $51 .68M

Company (Symbol)#

Date Filed

DateComm.

Shares/ Units (M)

Price

Shares Out (M)@

Lead, OtherUnderwriters

Gross(US$M)

Post-OfferingMarketCap (M)%

BioSante Pharmaceuticals Inc. (Lincolnshire, Ill.; BPAX)2

6/17/11

7/28/11

16S

$3

109.6

Jefferies

JMP Securities

Rodman & Renshaw

Roth Capital Partners

$48

$328.8

Cyclacel Pharmaceuticals Inc. (Berkeley Heights, N.J.; CYCC)3

4/26/11

7/1/11

7.62U

$1 .36

54.22

Leerink Swann LLC

Lazard Capital Markets

$10.36

$73.74

CytRx Corp. (Los Angeles; CYTR)4

12/13/10

7/27/11

39.2S and W for 39.2S

$0.52

149.1

Cowen and Co. LLC

Roth Capital Partners

$20.4

$77.53

NeoStem Inc. (New York; AMEX:NBS)

6/13/11

7/18/11

13.75U

$1.20

94.08

Lazard Capital Markets

JMP Securities (co-lead)

Morgan Joseph TriArtisan

Maxim Group LLC

National Securities Corp.

$16.5

$112.9

Ventrus Biosciences Inc. (New York; VTUS)5

7/14/11

7/14/11

4.5S

$10

11.73

Leerink Swann LLC

Lazard Capital (co-lead)

National Securities Corp.

Rodman & Renshaw

$45

$117.3

Total: $140.26M

Number of follow-on offerings in July: 5

Average value of July follow-ons: $28.05M

Number of follow-on offerings in 2011: 56

Total raised in follow-ons in 2011: $4,258.716M

Average value of follow-ons in 2011: $76.05M

Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

@ This column reflects the shares outstanding following the offering, when disclosed.

% Market capitalization is calculated based on the offering price.

Currency conversions are based on exchange rates at the time of the deal.

1 Horizon Pharma's overallotment option: 825,000 shares.

2 BioSante's overallotment option: 2.4M shares.

3 Each Cyclacel unit consists of one share of common stock and a five-year warrant to purchase half of an additional share at $1 .36 per share.

4 CytRx's overallotment option: 5.88M shares.

5 Ventrus' overallotment option: 675,000 shares.

Company (Symbol)#

Date Filed

Date Comm.

Shares/Units (M)

Price

Shares Out (M)@

Lead, Other Underwriters

Argos Therapeutics Inc. (Durham, N.C.; ARGS)

7/29/11

N/A

N/A

N/A

Lazard Capital Markets

Canaccord Genuity (co-lead)

Needham & Co.

BMO Capital Markets

$86.25

Clovis Oncology Inc. (Boulder, Colo.; CLVS)

6/23/11

N/A

N/A

N/A

J.P. Morgan

Credit Suisse (co-lead)

Leerink Swann

$149.5

Cutanea Life Sciences Inc. (CTNA)

11/5/10

2.3S

$6 - $7

3.9

Brean Murray, Carret & Co.

Rodman & Renshaw LLC (co-lead)

$14.95

Insys Therapeutics Inc. (Phoenix; INRX)

3/30/11

N/A

N/A

N/A

Wells Fargo Securities

JMP Securities (co-lead)

Oppenheimer & Co.

$55

Merrimack Pharmaceuticals Inc. (Cambridge, Mass.; MACK)

7/8/11

N/A

N/A

N/A

J.P. Morgan

BofA Merrill Lynch

Cowen & Co.

Oppenheimer & Co.

$172.5

NewLink Genetics Corp. (NLNK)

12/21/10

N/A

N/A

N/A

Wells Fargo

Cowen & Co. (co-lead)

Robert W. Baird

Canaccord Genuity

Needham & Co. LLC

$86.25

Supernus Pharmaceuticals Inc. (SUPN)

12/23/10

N/A

N/A

N/A

Citibank

Barclays Capital (co-lead)

Cowen and Co.

Stifel Nicolaus Weisel

$100

BioLineRx Ltd. (BLRX)1

9/24/10 (pulled 7/1/11)

N/A

N/A

N/A

JMP Securities

Oppenheimer & Co.

$40.25

Clarus Therapeutics Inc. (Northbrook, Ill.; CLRS)2

11/19/10 (pulled 7/1/11)

5S

$11-$13

18. 1

Piper Jaffray

Wells Fargo (Co-lead)

Lazard Capital Markets

Needham & Co.

$60

Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

General shelf registration statements are not included until action is taken on the filing.

* Stock symbols for companies seeking to complete IPOs are proposed.

@ This column reflects the shares outstanding following the offering, when disclosed.

N/A = Not available, applicable or reported.

The value of all offerings is based on either the midpoint of the price range listed in the company's SEC filing or the most recent closing stock price before the offering was announced. In some cases, the company has not disclosed the number of shares to be offered or a price range. Then, the value is the maximum aggregate offering price listed in the SEC filing.

1 BioLineRx instead listed its shares through American Depositary Receipts to be traded on Nasdaq under the ticker "BLRX."

2 Clarus withdrew, stating that the terms were not sufficiently attractive in the public marketplace.